
Glaucoma Therapeutics Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Beta Blockers, Alpha Adrenergic Agonists, Prostaglandins Analogues, Carbonic Anhydrase Inhibito
Description
Glaucoma Therapeutics Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Beta Blockers, Alpha Adrenergic Agonists, Prostaglandins Analogues, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), Indication (Open Angle Glaucoma, Angle Closure Glaucoma, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Geography
The glaucoma therapeutics market was valued at US$ 6.24 billion in 2023 and is expected to reach US$ 8.02 billion by 2031; it is estimated to record a CAGR of 3.2% during 2023-2031.
Key factors driving the market growth are the growing prevalence of glaucoma, rising awareness and early diagnosis of the disease, and increasing product launches are expected to drive the market growth. However, compliance issues with medication regimens and the high cost of treatments hinder the glaucoma therapeutics market growth.
Market Trends of the Glaucoma Therapeutics Market:
The gradual damage of the optic nerve—typically associated with high pressure inside the eye (intraocular pressure)—predominantly due to aging can lead to a group of eye diseases called Glaucoma, which can eventually result in irreversible blindness. One of the most common treatments for glaucoma is to reduce intraocular pressure by using eye drops. However, patient adherence to these eye drops can be challenging, and inadequate patient education can impede treatment success. Additionally, ocular hypotensive drugs can cause local and systemic side effects that may further complicate the treatment. Rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market. Recent advancements in glaucoma therapeutics have revolutionized the available treatments in the market. The use of nanoparticles with suitable structures and superior binding capabilities facilitates the bioavailability and efficacy of the drug. Sustained-release (SR) implants and other innovative drug delivery systems offer improved patient compliance and reduced side effects compared to conventional eye drops. Several companies are developing SR drug delivery systems as an alternative to topical delivery to potentially overcome barriers in treating POAG. As per the article published in PubMed Central in 2022, the only approved SR therapy for POAG by the Food and Drug Administration (FDA) is Bimatoprost SR (DurystaTM) from Allergan plc. Other SR therapies including bimatoprost ocular ring (Allergan), iDose (Glaukos Corporation), ENV515 (Envisia Therapeutics), OTX-TP (Ocular Therapeutix), OTX-TIC (Ocular Therapeutix), and latanoprost free acid SR (PolyActiva) are under investigation. SR drug delivery technology in POAG management may shift treatment paradigms and dramatically improve outcomes. Therefore, the development of novel drug delivery methods and combination therapies is likely to remain a key trend in the glaucoma therapeutics market.
Glaucoma therapeutics Market: Segmental Overview
The glaucoma therapeutics market is segmented on the basis of drug class, indication, and distribution channel.
By drug class, the market is divided into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandin analogs segment held a larger market share in 2023. Prostaglandin analogs are the first-line treatment for high intraocular pressure in glaucoma patients. They offer a once-a-day dosing, a significant reduction in intraocular pressure, and low systemic side effects. Thus, the benefits of prostaglandin analogs are responsible for the expansion of the glaucoma therapeutics market size.
The market, by indication, is segmented into open angle glaucoma, angle closure glaucoma, and others. The open-angle glaucoma segment held the largest glaucoma therapeutics market share in 2023 and is projected to register the highest CAGR from 2023 to 2031. Open-angle glaucoma is the most common form of glaucoma, which affects approximately 95% of individuals. Initially, it does not show any symptoms. However, at some point, an individual may start losing their side (peripheral) vision without treatment, resulting in total blindness.
By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023.
Glaucoma therapeutics Market: Geographical Overview
The scope of the glaucoma therapeutics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific is expected to register the fastest CAGR in the market from 2023 to 2031. Factors such as ongoing clinical studies for developing novel glaucoma therapies, as well as increasing healthcare expenditures in the region, contribute to the glaucoma therapeutics market growth in Asia Pacific. In terms of revenue, North America accounted for the largest glaucoma therapeutics market share in 2023.
Reasons to buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the glaucoma therapeutics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the glaucoma therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the glaucoma therapeutics market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
150 Pages
- 1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
- 4. Glaucoma Therapeutics Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 5. Glaucoma Therapeutics Market – Key Market Dynamics
- 5.1 Glaucoma Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.2.1 Mounting Incidence of Glaucoma Disease
- 5.2.2 Increasing Number of Product Launches, Collaborations, Acquisitions
- 5.3 Market Restraints
- 5.3.1 Medication Regimen Compliance Issues
- 5.4 Market Opportunities
- 5.4.1 Development of Wearable Technologies
- 5.5 Future Trends
- 5.5.1 Development of Novel Drug Delivery Methods
- 5.6 Impact of Drivers and Restraints:
- 6. Glaucoma Therapeutics Market – Global Market Analysis
- 6.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 Glaucoma Therapeutics Market Forecast Analysis
- 7. Glaucoma Therapeutics Market Analysis – by Drug Class
- 7.1 Beta Blockers
- 7.1.1 Overview
- 7.1.2 Beta Blockers: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 7.2 Alpha Adrenergic Agonists
- 7.2.1 Overview
- 7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 7.3 Prostaglandins Analogues
- 7.3.1 Overview
- 7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 7.4 Carbonic Anhydrase Inhibitors
- 7.4.1 Overview
- 7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 7.5 Combination Drugs
- 7.5.1 Overview
- 7.5.2 Combination Drugs: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8. Glaucoma Therapeutics Market Analysis – by Indication
- 8.1 Open Angle Glaucoma
- 8.1.1 Overview
- 8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.2 Angle Closure Glaucoma
- 8.2.1 Overview
- 8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 9. Glaucoma Therapeutics Market Analysis – by Distribution Channel
- 9.1 Hospital Pharmacy
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 9.2 Retail Pharmacy
- 9.2.1 Overview
- 9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 9.3 Online Pharmacy
- 9.3.1 Overview
- 9.3.2 Online Pharmacy: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10. Glaucoma Therapeutics Market – Geographical Analysis
- 10.1 Overview
- 10.2 North America
- 10.2.1 North America Glaucoma Therapeutics Market Overview
- 10.2.2 North America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.3 North America: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.2.3.1 North America: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Drug Class
- 10.2.4 North America: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.2.4.1 North America: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Indication
- 10.2.5 North America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.2.5.1 North America: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Distribution Channel
- 10.2.6 North America: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.2.6.1 North America: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.2.6.2 United States: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.6.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.2.6.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.2.6.2.3 United States: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.2.6.3 Canada: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.6.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.2.6.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.2.6.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.2.6.4 Mexico: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.6.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.2.6.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.2.6.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.3 Europe
- 10.3.1 Europe Glaucoma Therapeutics Market Overview
- 10.3.2 Europe: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.3.3 Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.3.3.1 Europe: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Drug Class
- 10.3.4 Europe: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.3.4.1 Europe: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Indication
- 10.3.5 Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.3.5.1 Europe: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Distribution Channel
- 10.3.6 Europe: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.3.6.1 Europe: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.3.6.2 Germany: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.3.6.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.3.6.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.3.6.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.3.6.3 France: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.3.6.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.3.6.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.3.6.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.3.6.4 United Kingdom: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.3.6.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.3.6.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.3.6.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.3.6.5 Italy: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.3.6.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.3.6.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.3.6.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.3.6.6 Spain: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.3.6.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.3.6.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.3.6.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.3.6.7 Rest of Europe: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.3.6.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.3.6.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.3.6.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.4 Asia Pacific
- 10.4.1 Asia Pacific Glaucoma Therapeutics Market Overview
- 10.4.2 Asia Pacific: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.4.3 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.4.3.1 Asia Pacific: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Drug Class
- 10.4.4 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.4.4.1 Asia Pacific: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Indication
- 10.4.5 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.4.5.1 Asia Pacific: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Distribution Channel
- 10.4.6 Asia Pacific: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.4.6.1 Asia Pacific: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.4.6.2 China: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.4.6.2.1 China: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.4.6.2.2 China: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.4.6.2.3 China: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.4.6.3 Japan: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.4.6.3.1 Japan: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.4.6.3.2 Japan: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.4.6.3.3 Japan: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.4.6.4 India: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.4.6.4.1 India: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.4.6.4.2 India: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.4.6.4.3 India: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.4.6.5 Australia: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.4.6.5.1 Australia: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.4.6.5.2 Australia: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.4.6.5.3 Australia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.4.6.6 South Korea: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.4.6.6.1 South Korea: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.4.6.6.2 South Korea: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.4.6.6.3 South Korea: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.4.6.7 Rest of APAC: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.4.6.7.1 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.4.6.7.2 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.4.6.7.3 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.5 Middle East and Africa
- 10.5.1 Middle East and Africa Glaucoma Therapeutics Market Overview
- 10.5.2 Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.5.3 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.5.3.1 Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Drug Class
- 10.5.4 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.5.4.1 Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Indication
- 10.5.5 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.5.5.1 Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Distribution Channel
- 10.5.6 Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.5.6.1 Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.5.6.2 Saudi Arabia: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.5.6.2.1 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.5.6.2.2 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.5.6.2.3 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.5.6.3 South Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.5.6.3.1 South Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.5.6.3.2 South Africa: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.5.6.3.3 South Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.5.6.4 United Arab Emirates: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.5.6.4.1 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.5.6.4.2 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.5.6.4.3 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.5.6.5 Rest of Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.5.6.5.1 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.5.6.5.2 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.5.6.5.3 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.6 South and Central America
- 10.6.1 South and Central America Glaucoma Therapeutics Market Overview
- 10.6.2 South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.6.3 South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.6.3.1 South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Drug Class
- 10.6.4 South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.6.4.1 South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Indication
- 10.6.5 South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.6.5.1 South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Distribution Channel
- 10.6.6 South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.6.6.1 South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.6.6.2 Brazil: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.6.6.2.1 Brazil: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.6.6.2.2 Brazil: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.6.6.2.3 Brazil: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.6.6.3 Argentina: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.6.6.3.1 Argentina: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.6.6.3.2 Argentina: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.6.6.3.3 Argentina: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 10.6.6.4 Rest of South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.6.6.4.1 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
- 10.6.6.4.2 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
- 10.6.6.4.3 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
- 11. Glaucoma Therapeutics Market – Industry Landscape
- 11.1 Growth Strategies in Glaucoma Therapeutics Market
- 11.2 Organic Growth Strategies
- 11.2.1 Overview
- 11.3 Inorganic Growth Strategies
- 11.3.1 Overview
- 12. Company Profiles
- 12.1 Alcon AG
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 AbbVie Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Bausch & Lomb Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Fera Pharmaceuticals, LLC
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Viatris Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Novartis AG
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Sun Pharmaceutical Industries Ltd
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Teva Pharmaceutical Industries Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 Thea Pharma Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 Santen Pharmaceutical Co., Ltd.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
- 13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms
- LIST OF TABLES
- Table 1. Glaucoma Therapeutics Market Segmentation
- Table 2. Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- Table 3. Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million) – by Drug Class
- Table 4. Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million) – by Indication
- Table 5. Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
- Table 6. North America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 7. North America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 8. North America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 9. North America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Country
- Table 10. United States: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 11. United States: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 12. United States: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 13. Canada: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 14. Canada: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 15. Canada: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 16. Mexico: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 17. Mexico: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 18. Mexico: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 19. Europe: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 20. Europe: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 21. Europe: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 22. Europe: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Country
- Table 23. Germany: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 24. Germany: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 25. Germany: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 26. France: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 27. France: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 28. France: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 29. United Kingdom: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 30. United Kingdom: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 31. United Kingdom: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 32. Italy: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 33. Italy: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 34. Italy: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 35. Spain: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 36. Spain: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 37. Spain: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 38. Rest of Europe: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 39. Rest of Europe: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 40. Rest of Europe: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 41. Asia Pacific: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 42. Asia Pacific: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 43. Asia Pacific: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 44. Asia Pacific: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Country
- Table 45. China: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 46. China: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 47. China: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 48. Japan: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 49. Japan: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 50. Japan: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 51. India: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 52. India: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 53. India: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 54. Australia: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 55. Australia: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 56. Australia: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 57. South Korea: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 58. South Korea: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 59. South Korea: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 60. Rest of APAC: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 61. Rest of APAC: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 62. Rest of APAC: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 63. Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 64. Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 65. Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 66. Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Country
- Table 67. Saudi Arabia: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 68. Saudi Arabia: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 69. Saudi Arabia: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 70. South Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 71. South Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 72. South Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 73. United Arab Emirates: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 74. United Arab Emirates: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 75. United Arab Emirates: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 76. Rest of Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 77. Rest of Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 78. Rest of Middle East and Africa: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 79. South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 80. South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 81. South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 82. South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Country
- Table 83. Brazil: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 84. Brazil: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 85. Brazil: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 86. Argentina: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 87. Argentina: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 88. Argentina: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 89. Rest of South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
- Table 90. Rest of South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Indication
- Table 91. Rest of South and Central America: Glaucoma Therapeutics Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
- Table 92. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
- Table 93. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
- Table 94. Glossary of Terms, Transiaent Protein Expression Market
- LIST OF FIGURES
- Figure 1. Glaucoma Therapeutics Market Segmentation, by Geography
- Figure 2. PEST Analysis
- Figure 3. Impact Analysis of Drivers and Restraints
- Figure 4. Glaucoma Therapeutics Market Revenue (US$ Million), 2021–2031
- Figure 5. Glaucoma Therapeutics Market Share (%) – by Drug Class (2023 and 2031)
- Figure 6. Beta Blockers: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- Figure 7. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- Figure 8. Prostaglandins Analogues: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- Figure 9. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- Figure 10. Combination Drugs: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- Figure 11. Others: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- Figure 12. Glaucoma Therapeutics Market Share (%) – by Indication (2023 and 2031)
- Figure 13. Open Angle Glaucoma: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- Figure 14. Angle Closure Glaucoma: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- Figure 15. Others: Glaucoma Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- Figure 16. Glaucoma Therapeutics Market Share (%) – by Distribution Channel (2023 and 2031)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.